Roche Holding’s much awaited drug for Alzheimer’s disease failed in a pair of large studies. Photograph: Getty ImagesRoche Holding’s much awaited drug for Alzheimer’s disease failed in a pair of large studies, a fresh disappointment in a research field marred with failures.
Both drugs are antibodies that target the protein that accumulates years before symptoms of Alzheimer’s appear, though they bind to beta amyloid in different ways. Eli Lilly also has a similar drug in development, with results expected next year.“Gantenerumab’s failure is likely due to lower-than-expected levels of beta-amyloid removal,” Peter Welford and colleagues at Jefferies wrote in a note.
Roche had brought gantenerumab back from the brink of failure once already. After it didn’t help patients more than a placebo in a study in 2014, the company ratcheted up the dose to try again. To show clearly whether the medicine did help patients, the Swiss drugmaker decided to run two simultaneous large studies.
Source: Healthcare Press (healthcarepress.net)
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: RSVPMagazine - 🏆 7. / 76 Read more »
Source: RSVPMagazine - 🏆 7. / 76 Read more »
Source: Herdotie - 🏆 15. / 63 Read more »
Source: VIP Magazine - 🏆 24. / 51 Read more »
Source: JOEdotie - 🏆 31. / 51 Read more »